About this trial

The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and associated vulnerability grade.

Eligibility criteria

Qualifiers

Patients referred for a clinically indicated CCTA and ICA with OCT imaging examinations;

Diagnosis of chronic coronary syndrome, known CAD, or stable angina; AND,

Patients with ACS that may undergo a CCTA and not refer directly to the Cath lab for revascularization procedures.

Disqualifiers

Contradictions to contrast;

Contraindications for beta blocker;

BMI >30;

High heart rate ≥75 BPM;

Trial design

Treatments tested in this trial

  • Deep Learning-based Vulnerable Plaque Detection and Assessment Tool

Treatment groups

200 Participants
are divided into 1 treatment group

Locations

1
Ospedale Di Voghera, Azienda Socio-Sanitaria Territoriale di Pavia27100, PaviaLombardy, Italy

Sponsors and collaborators

GE Healthcare

Lead sponsor

Azienda Socio-Sanitaria Territoriale di Pavia

Collaborator